ライフサイエンスコーパス: nonischemic

1 thresholds (<=0.80 as ischemic and >0.80 as nonischemic).

2 hemic patients showed a higher decrease than nonischemics.

3 usted hazard ratio for Chagasic versus other nonischemic: 1.49 (95% confidence interval, 1.15-1.94; P

4 +/- 9 y old) with ischemic (22 patients) and nonischemic (18 patients) heart failure completed the st

5 ents (men, 88%; age, 65 years [58-71 years]; nonischemic, 47%).

6 up for ischemic (19% DZ, 59% TZ, 22% NZ) and nonischemic (6% DZ, 45% TZ, 15% NZ) patients.

7 e 50% and 19% of patients, both ischemic and nonischemic, achieved an LV ejection fraction >/= 40%.

8 noninvasive differentiation of ischemic and nonischemic acute heart failure (AHF) in the emergency d

9 troscopy in nondiabetic, lean, predominantly nonischemic, advanced heart failure patients at the time

10 gnificantly higher in ischemic compared with nonischemic AHF (1097 [604-1525] pg/mL versus 800 [427-1

11 gnificantly higher in ischemic compared with nonischemic AHF patients (0.040 [0.010-0.306] mug/L vers

12 and cardiomyocyte damage than patients with nonischemic AHF.

13 which were ischemic and 24.5% of which were nonischemic, alternate diagnoses to myocardial infarctio

14 s finding is present in 30% of patients with nonischemic and 15% of patients with ischemic cardiomyop

15 clerotic stroke, hypertensive heart disease, nonischemic and Chagas cardiomyopathies, rheumatic heart

16 horylation of RyR2 in patients and mice with nonischemic and ischemic forms of HF.

17 with symptomatic heart failure (ischemic and nonischemic) and an ejection fraction (EF) of 40% or les

18 1.4 per 100 person-years for Chagasic, other nonischemic, and ischemic patients, respectively-adjuste

19 % functional mitral regurgitation [FMR] [84% nonischemic] and 5% organic mitral regurgitation [OMR] [

20 effect on CNV formation in a rabbit model of nonischemic angiogenesis.

21 ly inhibited in cardiomyocytes isolated from nonischemic area 7 days after MI.

22 S2814 on RyR2 was increased in patients with nonischemic, but not with ischemic, HF.

23 hemic heart disease, and its similarities to nonischemic canine results support the translational uti

24 classified ganglia from normal, scarred, and nonischemic cardiomyopathic hearts without scar as NL (n

25 Mean neuronal size in normal, scarred, and nonischemic cardiomyopathic hearts without scar groups w

26 The nonischemic cardiomyopathies are a diverse group of card

27 has grown, an increasing number of patients nonischemic cardiomyopathies are requiring therapy to re

28 iomyopathy and peripartum cardiomyopathy are nonischemic cardiomyopathies that often afflict previous

29 ction of ischemic heart disease, and discuss nonischemic cardiomyopathies unique to or prevalent in w

30 ogeneses, including coronary artery disease, nonischemic cardiomyopathies, and arrhythmias.

31 e erratic/patchy scar patterns seen in other nonischemic cardiomyopathies.

32 ardiomyopathy, myocarditis, and ischemic and nonischemic cardiomyopathies.

33 d the spectrum of imaging appearances of the nonischemic cardiomyopathies.

34 short axis) was applied in 31 patients with nonischemic cardiomyopathy (50+/-18 years).

35 Forty-five patients with nonischemic cardiomyopathy (60+/-16 years; left ventricu

36 Nineteen consecutive patients with nonischemic cardiomyopathy (age 58+/-14 years, 79% men,

37 ependent correlates of LVT regression were a nonischemic cardiomyopathy (hazard ratio [HR]: 2.74; 95%

38 reparations from human hearts with end-stage nonischemic cardiomyopathy (heart failure, n=10) and non

39 Enrollment criteria were new diagnosis of nonischemic cardiomyopathy (left ventricular ejection fr

40 ysfunction in patients with left ventricular nonischemic cardiomyopathy (LVCM).

41 2000 patients with ischemic (n=805, 40%), or nonischemic cardiomyopathy (n=927, 46%), or congenital/i

42 Compared with patients with nonischemic cardiomyopathy (NICM) and ischemic cardiomyo

43 ricular tachyarrhythmias among patients with nonischemic cardiomyopathy (NICM) enrolled in the MADIT-

44 Small-scale studies focused mainly on nonischemic cardiomyopathy (NICM) have shown that a subs

45 of protecting patients with newly diagnosed nonischemic cardiomyopathy (NICM) or ischemic cardiomyop

46 therapy in ischemic cardiomyopathy (ICM) and nonischemic cardiomyopathy (NICM) patients and to evalua

47 rse cardiovascular outcomes in patients with nonischemic cardiomyopathy (NICM).

48 T-D) versus pacing (CRT-P) for patients with nonischemic cardiomyopathy (NICM).

49 ociation [NYHA] functional class I or II) or nonischemic cardiomyopathy (NYHA functional class II onl

50 , lower LVEF (OR, 1.15 [95% CI, 1.10-1.19]), nonischemic cardiomyopathy (OR, 1.24 [95% CI, 1.09-1.36]

51 schemic cardiomyopathy (r=-0.5, P=0.006) and nonischemic cardiomyopathy (r=-0.45, P=0.028).

52 Unipolar low-voltage distribution in nonischemic cardiomyopathy allows categorization of scar

53 alence of LAVA adjacent to CAs was higher in nonischemic cardiomyopathy and arrhythmogenic right vent

54 Compared with patients with nonischemic cardiomyopathy and ischemic cardiomyopathy,

55 ival between CCMP patients and patients with nonischemic cardiomyopathy and ischemic cardiomyopathy.

56 Female patients were more likely to have nonischemic cardiomyopathy and left bundle branch block

57 ter ventricular tachycardia (VT) ablation in nonischemic cardiomyopathy are high and the optimal proc

58 rsal of end-stage heart failure secondary to nonischemic cardiomyopathy can be achieved in a substant

59 lic heart failure as a result of ischemic or nonischemic cardiomyopathy despite receiving guideline-d

60 res with scar morphology and distribution in nonischemic cardiomyopathy has not been investigated.

61 We randomized 16 patients with nonischemic cardiomyopathy in a double-blind fashion to

62 ong Latin American immigrants diagnosed with nonischemic cardiomyopathy in Los Angeles.

63 Nonischemic cardiomyopathy is a common cause of left ven

64 d, crossover, randomized phase II-a trial of nonischemic cardiomyopathy patients with left ventricula

65 d, crossover, randomized phase II-a trial of nonischemic cardiomyopathy patients with left ventricula

66 ocities, myocardial scar, and wall motion in nonischemic cardiomyopathy patients.

67 nts with chronic advanced heart failure from nonischemic cardiomyopathy receiving the Heartmate II LV

68 Of 435 patients with nonischemic cardiomyopathy referred for VT ablation, 21

69 We studied 28 patients with nonischemic cardiomyopathy requiring VAD support consist

70 alence of LAVAs adjacent to PN was higher in nonischemic cardiomyopathy than in ischemic cardiomyopat

71 n Trial II (MADIT-II), the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation Trial (D

72 Fifteen patients with nonischemic cardiomyopathy underwent late gadolinium-enh

73 in endomyocardial biopsies of patients with nonischemic cardiomyopathy was positively correlated wit

74 In 235 patients with chronic ischemic and nonischemic cardiomyopathy with a left ventricular eject

75 Patients had nonischemic cardiomyopathy with left bundle branch block

76 relate distinct scar distributions found in nonischemic cardiomyopathy with ventricular tachycardia

77 e (80% in ischemic cardiomyopathy and 63% in nonischemic cardiomyopathy) was achieved.

78 alities (myocarditis, takotsubo syndrome, or nonischemic cardiomyopathy) was present in 20.7% (24/116

79 s involving 8716 4 (1781 patients) addressed nonischemic cardiomyopathy, 6 (4414 patients) ischemic c

80 h reduced ejection fraction, 1300 with other nonischemic cardiomyopathy, and 1057 with ischemic cardi

81 49 patients (15 ischemic cardiomyopathy, 15 nonischemic cardiomyopathy, and 14 arrhythmogenic right

82 ischemic cardiomyopathy without AMI, 28% had nonischemic cardiomyopathy, and 17% had a cardiac cause

83 All 4 patients had nonischemic cardiomyopathy, and 3 had left ventricular a

84 pproaches have increased ablation success in nonischemic cardiomyopathy, but the use for postinfarcti

85 In this pilot study of patients with nonischemic cardiomyopathy, itMSC therapy was safe, caus

86 ed with ADHD stimulants included arrhythmia, nonischemic cardiomyopathy, Takotsubo cardiomyopathy, an

87 In the 6 patients with nonischemic cardiomyopathy, the low-voltage area by far

88 In patients with nonischemic cardiomyopathy, VT and septal scar, delayed

89 ith increased mortality rate in ischemic and nonischemic cardiomyopathy, which may be attributed to e

90 heart failure (HF) secondary to ischemic and nonischemic cardiomyopathy.

91 myocarditis, neurogenic pulmonary edema, and nonischemic cardiomyopathy.

92 reas of abnormal innervation than those with nonischemic cardiomyopathy.

93 s often close to CAs and PN in patients with nonischemic cardiomyopathy.

94 red ECV and segmental myocardial function in nonischemic cardiomyopathy.

95 of adverse clinical outcome in patients with nonischemic cardiomyopathy.

96 creatinine<1.0 mg/dL, QRS 130 to 160 ms, and nonischemic cardiomyopathy.

97 ntricular tachycardias (VT) in patients with nonischemic cardiomyopathy.

98 and reduce infarct size in both ischemic and nonischemic cardiomyopathy.

99 f arrhythmogenic substrates in patients with nonischemic cardiomyopathy.

100 morphology and distribution in patients with nonischemic cardiomyopathy.

101 r tachycardia circuit sites in patients with nonischemic cardiomyopathy.

102 tachycardia (VT) substrate is challenging in nonischemic cardiomyopathy.

103 of arrhythmogenic substrate in patients with nonischemic cardiomyopathy.

104 substrate for arrhythmia in human end-stage nonischemic cardiomyopathy.

105 hology and functional characteristics of the nonischemic cardiomyopathy.

106 emic cardiomyopathy compared with those with nonischemic cardiomyopathy.

107 ty patients had ischemic and 37 patients had nonischemic cardiomyopathy.

108 or death (HR, 1.99; P<0.001) as left BBB and nonischemic cardiomyopathy.

109 -defibrillator implantation in patients with nonischemic cardiomyopathy.

110 Ds with all-cause mortality in patients with nonischemic cardiomyopathy.

111 en known for decades as a reversible form of nonischemic cardiomyopathy.

112 h (primary prevention ICDs) in patients with nonischemic cardiomyopathy.

113 emia-tolerant MSCs (itMSCs) in patients with nonischemic cardiomyopathy.

114 rapy (control) in at least 100 patients with nonischemic cardiomyopathy.

115 cing all-cause mortality among patients with nonischemic cardiomyopathy.

116 of various causes in adults with ischemic or nonischemic cardiomyopathy.

117 duce all-cause mortality among patients with nonischemic cardiomyopathy.

118 Differentiation of ischemic from nonischemic cardiomyopathy; evaluation of myocardial per

119 In contrast, women were more likely to have nonischemic cause of SCD than men (28.3% versus 24.3%, P

120 ed in 63.8% of women with MINOCA (74/116), a nonischemic cause was identified in 20.7% (24/116) of th

121 ial injury (troponin T >= 0.03 ng/mL without nonischemic cause) and death up to 7 postoperative days.

122 In the absence of clear demonstration of a nonischemic cause, treatment should include guideline-re

123 sistently demonstrate an ability to identify nonischemic causes (myocarditis, infiltrative disease).

124 der at the time of SCD and more commonly had nonischemic causes.

125 Fifty-five patients with a nonischemic central retinal vein occlusion (CRVO) who we

126 y when compared with naive livers as well as nonischemic-challenged steatotic livers (P < 0.05) as as

127 atively homogenous group of 53 patients with nonischemic chronic cardiomyopathy (CCM) was selected fo

128 addition to ischemic heart disease, certain nonischemic conditions may also have sex-specific differ

129 ive capacity of hCPCs in young patients with nonischemic congenital heart defects for potential use i

130 capacity of CSCs in very young patients with nonischemic congenital heart defects has not been explor

131 evaluated Ngb mRNA and protein expression in nonischemic control as well as ischemic mice and its eff

132 te, and it is the first to associate it with nonischemic CRVO.

133 By using two models of infarction, nonischemic cryoinjury and the pathologically relevant c

134 s with ischemic DCM but not in patients with nonischemic DCM.

135 rwent robotic mitral valve repair for severe nonischemic degenerative MR.

136 We profiled the microbiomes of neuropathic nonischemic DFUs without clinical evidence of infection

137 Patients with nonischemic dilated cardiomyopathy (DCM) may be at lower

138 Nonischemic dilated cardiomyopathy (DCM) often has a gen

139 s, both in ischemic cardiomyopathy (ICM) and nonischemic dilated cardiomyopathy (DCM).

140 entricular tachycardia (VT) in patients with nonischemic dilated cardiomyopathy (NIDCM) are insuffici

141 of ventricular tachycardia (VT) ablation in nonischemic dilated cardiomyopathy (NIDCM) are insuffici

142 sequences were obtained in 20 patients with nonischemic dilated cardiomyopathy (NIDCM), 20 patients

143 and prognostic information in patients with nonischemic dilated cardiomyopathy (NIDCM).

144 cardiomyopathy, few studies exist in chronic nonischemic dilated cardiomyopathy (NIDCM).

145 tients (18 ischemic cardiomyopathy [ICM], 13 nonischemic dilated cardiomyopathy [NICM], 15 arrhythmog

146 c fibrosis and inflammation in patients with nonischemic dilated cardiomyopathy and inflammatory card

147 In patients with nonischemic dilated cardiomyopathy and VT, endocardial a

148 entricular tachycardia (VT) in patients with nonischemic dilated cardiomyopathy can be challenging be

149 , the most common cause of heart failure was nonischemic dilated cardiomyopathy in 27.5% (whites, 19.

150 Risk stratification of patients with nonischemic dilated cardiomyopathy is primarily based on

151 ography (TTE) in ischemic cardiomyopathy and nonischemic dilated cardiomyopathy patients evaluated fo

152 ive patients with ischemic cardiomyopathy or nonischemic dilated cardiomyopathy undergoing cardiovasc

153 atients (aged 59+/-15 years, 80% males) with nonischemic dilated cardiomyopathy who underwent CA.

154 l patients (164 ischemic cardiomyopathy, 150 nonischemic dilated cardiomyopathy), the mean left ventr

155 of endocardial and adjuvant epicardial CA in nonischemic dilated cardiomyopathy.

156 chyarrhythmias/sudden death in patients with nonischemic dilated cardiomyopathy.

157 ictors of arrhythmic events in patients with nonischemic dilated cardiomyopathy.

158 on for sudden cardiac death in patients with nonischemic dilated cardiomyopathy.

159 tic information beyond LVEF in patients with nonischemic dilated cardiomyopathy.

160 D34(+) cell transplantation in patients with nonischemic dilated cardiomyopathy.

161 ls of cardiomyopathy, including ischemic and nonischemic dilated cardiomyopathy.

162 (HR, 0.39 [CI, 0.23 to 0.68]) and those with nonischemic disease (HR, 0.44 [CI, 0.17 to 1.12]).

163 uidelines that do not adequately account for nonischemic diseases and events.

164 d in a subset of patients, both ischemic and nonischemic, early improvement in myocardial structure a

165 the limit of detection in combination with a nonischemic ECG may successfully rule out AMI in patient

166 epartment with normal initial troponin and a nonischemic ECG.

167 e limit of detection (<0.005 microg/L) and a nonischemic electrocardiogram (ECG) to rule out AMI in a

168 Eligible patients had a nonischemic electrocardiogram determined and high-sensit

169 ry were age <50 years (odds ratio [OR] 2.5), nonischemic etiology (OR 5.4), time since initial diagno

170 5% primary prevention ICD) with ischemic and nonischemic etiology undergoing first ICD implant at 1 o

171 Predictors of reverse remodeling were nonischemic etiology, female sex, and a wider QRS durati

172 mic attack 114.5 pmol/l (85.3 to 138.8); and nonischemic event 102.8 pmol/l (76.4 to 137.6; both grou

173 c attack (n = 16; 8.5%) and to patients with nonischemic events (n = 49; 25.9%): median (interquartil

174 A normal ECG was even more common among nonischemic female subjects with SCD (27.8% versus 16.2%

175 scularization was deferred on the basis of a nonischemic FFR (>0.75).

176 aneous coronary intervention on the basis of nonischemic FFR in patients with an initial presentation

177 Among 6413 patients with a nonischemic FFR, 12.6% received PCI and 87.4% were treat

178 ronary intervention deferred on the basis of nonischemic FFR.

179 A nonischemic forearm test demonstrated a lack of increase

180 reticulum Ca(2+) leak and HF development in nonischemic forms of HF such as transverse aortic constr

181 y differentiate between ischemic and various nonischemic forms of myocardial injury, it may be helpfu

182 Mechanisms and treatments of nonischemic functional mitral regurgitation (NIMR) are n

183 ator implantation is recommended in dilated, nonischemic heart disease and left ventricular ejection

184 nhibition exerts an antiremodeling effect in nonischemic heart disease in humans.

185 14 years; 79% men) with sustained VT due to nonischemic heart disease were included.

186 n of 2 failed prior ablation procedures; 71% nonischemic heart disease).

187 In patients with recurrent VT due to nonischemic heart disease, catheter ablation is often us

188 arkers may improve identification of SBHF in nonischemic heart disease.

189 HF is present among adults with HF caused by nonischemic heart disease.

190 impaired clinical outcomes in patients with nonischemic heart disease.

191 ablation of ventricular tachycardia (VT) in nonischemic heart diseases can be challenging, and outco

192 s (CFBs) to promote cardiac fibrosis (CF) in nonischemic heart failure (HF).

193 vious history of MI compared with those with nonischemic heart failure and correlated with survival,

194 The majority (71%) of patients with nonischemic heart failure etiology or functional block r

195 Whether the myocardium in nonischemic heart failure experiences oxygen limitation

196 g after myocardial ischemia, but its role in nonischemic heart failure is poorly understood.

197 Our study suggests that novel treatments for nonischemic heart failure should focus on efforts to dir

198 an affordable and effective new therapy for nonischemic heart failure.

199 atients were younger and more likely to have nonischemic heart failure.

200 tratified by diabetes status and ischemic or nonischemic HF and history of revascularization in the S

201 study examined the impact of ischemic versus nonischemic HF and previous revascularization on long-te

202 r HF diagnosis (classified as ischemic HF or nonischemic HF based on the presence of IHD) was assesse

203 d patients were more likely to be women with nonischemic HF etiology, higher baseline blood pressure,

204 F HR: 0.81; 95% CI: 0.69 to 0.95; p = 0.009; nonischemic HF HR: 0.97; 95% CI: 0.79 to 1.20; p = 0.802

205 The risk of nonischemic HF increased rapidly after RA onset, in cont

206 The increased risk of nonischemic HF occurred early and was associated with RA

207 Real-time videomicroscopy of T cells from nonischemic HF patients or from mice with HF induced by

208 l infiltration in the fibrotic myocardium of nonischemic HF patients, as well as the protection from

209 r subsequent HF (any type), ischemic HF, and nonischemic HF were between 1.22 and 1.27.

210 Patients with nonischemic HF were randomized to routine versus selecti

211 k of HF overall and by subtype (ischemic and nonischemic HF) in patients with RA and to assess the im

212 I-1c (BNP116.I-1c) in a preclinical model of nonischemic HF, and to assess thoroughly the safety of B

213 In patients with nonischemic HF, routine CMR does not yield more specific

214 of CMR will yield more specific diagnoses in nonischemic HF.

215 T cells are major contributors to nonischemic HF.

216 mic signatures of patients with ischemic and nonischemic HF.

217 fferences between patients with ischemic and nonischemic HF.

218 f perivascular CF and cardiac dysfunction in nonischemic HF.

219 tricle and atrium in a large animal model of nonischemic HF.

220 ith all HF types but was most pronounced for nonischemic HF.

221 A total of 1121 patients with nonischemic HFREF from the beta-blocker Evaluation of Su

222 Using various in vivo, nonischemic, hindlimb xenotransplant models (immunocompe

223 scle regions of interest in the ischemic and nonischemic hindlimbs for quantification of regional cha

224 eased Galphaq palmitoylation in ischemic and nonischemic hindlimbs in vivo In summary, we demonstrate

225 of reduction was similar in the cohorts with nonischemic (HR, 0.81 [CI, 0.72 to 0.91]) and ischemic (

226 ped in a clinically relevant murine model of nonischemic hypertrophic CHF, transverse aortic constric

227 ive acting adenosine, we reasoned that short nonischemic hypoxia also protects against hepatic IRI.

228 myopathy pathogenesis was ischemic in 21 and nonischemic in 13 patients with a mean left ventricular

229 ischemic (acute myocardial infarction), and nonischemic injury to the myocardium (myocarditis) and t

230 ects; p < 0.05), and focal fibrosis (59% had nonischemic late gadolinium enhancement, as compared wit

231 hanges; the roles of sensitive indicators of nonischemic left ventricular (LV) dysfunction, such as L

232 utcome of competitive athletes with isolated nonischemic left ventricular (LV) scar as evidenced by c

233 erring percutaneous coronary intervention in nonischemic lesions by fractional flow reserve (FFR) is

234 Compared with nonischemic lesions, ischemic lesions had smaller MLD (1

235 chemic lesions and a higher rate of MACE for nonischemic lesions.

236 Nonischemic LGE patterns (midmyocardial/subepicardial) w

237 o a degree that was greater than the control nonischemic limb.

238 Control nonischemic limbs were injected with phosphate buffered

239 Isolated nonischemic LV LGE with a stria pattern may be associate

240 median age 65 years [59-71], 15% female, 50% nonischemic, median ejection fraction 31%) underwent 144

241 rtery diameter measurement were performed in nonischemic mice after unilateral 10-minute exposure to

242 O(4)(-) uptake by 4- to 5-fold compared with nonischemic muscle treated with only AAV9-hNIS.

243 CoV-2) infection increase the risk for acute nonischemic myocardial injury and acute myocardial infar

244 s that may assist in differentiating between nonischemic myocardial injury, type 1 MI, and type 2 MI.

245 e laboratory identified ischemia-related and nonischemic myocardial injury.

246 rdial injury, including 5 subtypes of MI and nonischemic myocardial injury.

247 ischemia is categorized as acute or chronic nonischemic myocardial injury.

248 f remote cardiac macrophages residing in the nonischemic myocardium in mice with chronic heart failur

249 ction (n=126) and CHF of ischemic (n=562) or nonischemic (n=87) etiology.

250 Deep sequencing of RNA isolated from paired nonischemic (NICM; n=8) and ischemic (ICM; n=8) human fa

251 c magnetic resonance imaging consistent with nonischemic, nonfailing diabetic cardiomyopathy (reduced

252 1) viral genome particles) was injected into nonischemic or ischemic gastrocnemius muscles of C57Bl/6

253 eft ventricular systolic dysfunction, either nonischemic or ischemic.

254 etiology was categorized as Chagasic, other nonischemic, or ischemic cardiomyopathy.

255 and made up the response score (female sex, nonischemic origin, left bundle-branch block, QRS >/=150

256 rt failure of any cause and heart failure of nonischemic origin.

257 ces of chronic heart failure of ischemic and nonischemic origin.

258 s also used to determine whether there was a nonischemic pathogenesis for myocardial necrosis.

259 o a new IRA diagnosis in 31%, a diagnosis of nonischemic pathogenesis in 15%, or either in 46% (95% C

260 y lead to a new IRA diagnosis or elucidate a nonischemic pathogenesis.

261 In contrast, LBBB is most commonly caused by nonischemic pathologies.

262 enital/inherited heart disease, and 1% among nonischemic patients (P=0.02).

263 ilure results in similar midterm survival to nonischemic patients in hospital survivors.

264 s controls, calf biopsies of nondiabetic and nonischemic patients undergoing saphenous vein stripping

265 low-up (56.7% vs. 27.5%, P = 0.011) than the nonischemic patients.

266 cted only 10% of inferior segments in 75% of nonischemic patients.

267 A similar benefit was not seen in the nonischemic patients.

268 /C-type pattern of fatty infiltration and/or nonischemic pattern LGE).

269 A nonischemic pattern of CMR abnormalities (myocarditis, t

270 rol; a similar trend was not observed in the nonischemic population.

271 ac immune composition in the standard murine nonischemic, pressure-overload heart failure model.

272 The ischemic to nonischemic ratio of (99m)Tc-RP805 was significantly inc

273 ir origin and roles in post-MI remodeling of nonischemic remote myocardium, however, remain unclear.

274 urthermore, it is currently not known if the nonischemic remote zone recruits monocytes.

275 y higher in victims of ischemic (34.2%) than nonischemic SCD (13.4%; P<0.001) or controls (17.6%; P<0

276 ol study included (1) consecutive victims of nonischemic SCD (n=223), (2) consecutive victims of isch

277 rpose of this study was to determine whether nonischemic SCD has a similar familial background, which

278 ee relatives did not differ from controls in nonischemic SCD victims (P=0.155).

279 is not significantly increased in victims of nonischemic SCD, suggesting a larger role of sporadic oc

280 rrence than inherited traits as the cause of nonischemic SCD.

281 -1); P=0.001), whereas no effect was seen in nonischemic segments (-2.19+/-0.48 versus -2.18+/-0.54 s

282 ifferent concentrations between ischemic and nonischemic segments.

283 sic cardiomyopathy (CC) is the most frequent nonischemic substrate causing left ventricular (LV) tach

284 Patients with nonischemic systolic heart failure (HF) have increased r

285 Background Patients with nonischemic systolic heart failure are at an increased r

286 n fraction (RVEF) can identify patients with nonischemic systolic heart failure more likely to benefi

287 Assess the Efficacy of ICDs in Patients with Nonischemic Systolic Heart Failure on Mortality), patien

288 c Heart Failure on Mortality), patients with nonischemic systolic heart failure randomized to ICD or

289 of a primary prevention ICD in patients with nonischemic systolic heart failure warrants further inve

290 ng to the duration of HF among patients with nonischemic systolic HF enrolled in the DANISH (Danish S

291 was observed in 236 eyes (121 ischemic, 115 nonischemic) that were compared with a control group (10

292 include differentiation between ischemic and nonischemic types, identification of any complications,

293 that shock in a swine model of ischemic and nonischemic ventricular fibrillation arrest.

294 nt of normal versus abnormal (SSS >/= 4) and nonischemic versus ischemic (SDS >/= 2) studies was exce

295 lower radiation exposure than patients with nonischemic VT (total fluoroscopy time, 2.53 [1.22-11.22

296 VT substrate: (1) ischemic VT (IVT) and (2) nonischemic VT and depending on the presence of an epica

297 ibe the outcomes after catheter ablation for nonischemic VT in a large cohort and to compare the elec

298 were performed in 41 patients (22 IVT and 19 nonischemic VT).

299 Relative 201Tl retention (ischemic/nonischemic) was reduced immediately postocclusion in di

300 s with cardiomyopathy (n = 9 ischemic, n = 4 nonischemic) who were scheduled to undergo ablation of d